Data Dictionary: Belgian Cancer Registry: Difference between revisions
From Beacon
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
! Variable !! Description | ! Variable !! Description | ||
|- | |- | ||
| Unique patient identification including demographic parameters || (i.e., date of birth | | Unique patient identification including demographic parameters || (i.e., date of birth, zip code) and unique identification of the care program and hospital | ||
|- | |- | ||
| Diagnosis according to international classification || including date of incidence | | Diagnosis according to international classification || including date of incidence | ||
| Line 24: | Line 24: | ||
| Disease-free survival and survival || (i.e., treatment outcome) | | Disease-free survival and survival || (i.e., treatment outcome) | ||
|- | |- | ||
| Date of death || | | Date of death || | ||
|- | |||
| Gender || (Male – Female – Both sexes together) | |||
|- | |||
| Region || (Belgium – Flanders – Wallonia – Brussels) | |||
|- | |||
| Incidence year || | |||
|- | |||
| 5-year age group || (only for absolute numbers and gross incidence) | |||
|} | |} | ||
Revision as of 14:11, 30 April 2024
Go back to Belgium page
Source: Click here to learn more.
| Variable | Description |
|---|---|
| Unique patient identification including demographic parameters | (i.e., date of birth, zip code) and unique identification of the care program and hospital |
| Diagnosis according to international classification | including date of incidence |
| Tumor stage (cTNM) | |
| Conclusion of the pathological report | (including pTNM) |
| Treatment with reference to guidelines or justification of deviation | |
| Follow-up plan | |
| Side effects | |
| Disease-free survival and survival | (i.e., treatment outcome) |
| Date of death | |
| Gender | (Male – Female – Both sexes together) |
| Region | (Belgium – Flanders – Wallonia – Brussels) |
| Incidence year | |
| 5-year age group | (only for absolute numbers and gross incidence) |
Source: Click here to learn more.
| Aspects of Participation and Screening Test Usage |
| Aspects of participation |
| Use of the screening test in the target group |
| Results obtained and their use (including cancer detection rate, sensitivity, and specificity) |
| Cyto-histopathology register |
| Results of further follow-up |